HC Wainwright Downgrades Pacira Biosciences to Neutral, Price Target is $36.50
MT newswire2026/10/09 11:2407:24 AM EDT, 10/09/2026 (MT Newswires) -- Pacira Biosciences (PCRX) has an average rating of hold and mean price target of $34.79, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asian Stocks Rebound, Nikkei Up 3.4%, but Can They Lead Wall Street?
Brent Crude Fell 12.5% But Former Biden Advisor Warns Iran War Could Return
Cathie Wood Blames Anthropic’s CEO for AI Panic: Why Attack a Company Her Fund Backs?
Anthropic's $1.5 Trillion IPO: What Investors Should Know Before Buying
Crypto prices
More
